Single User License
INR 339810
Site License
INR 679620
Corporate User License
INR 1019430

Service Tax Additional

select a format
Price

Single User License
USD 4995
Site License
USD 9990
Corporate User License
USD 14985

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Allergic Rhinitis-Japan Drug Forecast and Market Analysis to 2024

Allergic Rhinitis-Japan Drug Forecast and Market Analysis to 2024


  Request for Sample Report

Executive Summary

Allergic Rhinitis-Japan Drug Forecast and Market Analysis to 2024

Summary

AR is becoming an increasingly prevalent condition, with the most common form being moderate to severe in nature (Baena-Cagnani et al., 2015). According to the European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will suffer from an allergy by 2027 (Papadopoulos et al., 2012). The allergic rhinitis (AR) market has declined very slowly over the past decade, as has it become saturated with relatively efficacious standard therapies, such as antihistamines (AHs), intranasal corticosteroids (INCS), and leukotriene receptor antagonists (LRAs), and has also been facing increasing generic competition. Despite the rising prevalence of AR, and a large patient population that is dissatisfied with the current treatment options, the market size for symptomatic therapies alone is set to shrink, as the remaining branded products lose patent protection. There is an increasing shift in the transfer of prescription AR products to over-the-counter (OTC) status, which is driving patients to pharmacies rather than to physicians, further diluting the prescription AR market. The immense, crowded generic AR market has been largely unappealing to drug manufacturers. Consequently, only two symptomatic therapies are expected to launch before 2024.

Sales of AR products in Japan were USD 1.89 billion in 2014. As in the global markets, the growth in the Japanese AR market will be fueled mainly by the uptake of the new AITs, and will be offset by the patent expiry of the best-selling AHs in 2013, and Merck's INCS, Nasonex, in 2017.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Overview of Allergic Rhinitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in Japan from 2014-2024.

Analysis of the impact of key events as well the drivers and restraints affecting Japan Allergic Rhinitis market.

Reasons To Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Allergic Rhinitis.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2014-2024 in Japan.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 8

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

2.3 Upcoming Related Reports 10

3 Disease Overview 11

3.1 Etiology and Pathophysiology 11

3.2 Symptoms 14

3.3 Classification 15

3.3.1 Seasonal and Perennial AR 15

3.3.2 ARIA Classification of AR 15

3.4 Diagnosis 16

3.5 Quality of Life 18

4 Disease Management 19

4.1 Diagnosis and Treatment Overview 19

4.1.1 Diagnosis 19

4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20

4.1.3 Clinical Practice 23

4.2 Japan 32

5 Competitive Assessment 35

5.1 Overview 35

5.2 Oral H1 Antihistamines 39

5.2.1 Overview 39

5.2.2 Efficacy 48

5.2.3 Safety 49

5.2.4 SWOT Analysis 51

5.2.5 Forecast 52

5.3 Intranasal Antihistamines 52

5.4 Intranasal Corticosteroids 55

5.4.1 Overview 55

5.4.2 Efficacy 62

5.4.3 Safety 64

5.4.4 SWOT Analysis 65

5.4.5 Forecast 66

5.5 Combination Intranasal Corticosteroids/Antihistamines 66

5.5.1 Dymista 66

5.6 Decongestants 75

5.6.1 Overview 75

5.7 Intranasal Anticholinergics 78

5.7.1 Overview 78

5.8 Leukotriene Receptor Antagonists 79

5.8.1 Overview 79

5.9 Cromones 82

5.9.1 Overview 82

5.10 Thromboxane A2 Receptor Antagonists 83

5.10.1 Overview 83

5.11 TH2 Cytokine Inhibitors 84

5.11.1 Overview 84

6 Unmet Need and Opportunity 85

6.1 Overview 85

6.2 Pharmacist Education 87

6.2.1 Unmet Need 87

6.2.2 Gap Analysis 89

6.2.3 Opportunity 90

6.3 Patient Compliance With Intranasal Corticosteroids and Antihistamines 92

6.3.1 Unmet Need 92

6.3.2 Gap Analysis 93

6.3.3 Opportunity 95

6.4 More Convenient and More Patient-Friendly Immunotherapies 98

6.4.1 Unmet Need 98

6.4.2 Gap Analysis 99

6.4.3 Opportunity 101

6.5 Primary Care Physician Education 102

6.5.1 Unmet Need 102

6.5.2 Gap Analysis 104

6.5.3 Opportunity 105

7 Pipeline Assessment 107

7.1 Promising Drugs in Clinical Development 108

7.1.1 S-555739 108

7.1.2 HP-3060 114

8 Market Outlook 119

8.1 Japan 119

8.1.1 Forecast 119

8.1.2 Key Events 124

8.1.3 Drivers and Barriers 124

9 Appendix 128

9.1 Bibliography 128

9.2 Abbreviations 141

9.3 Methodology 146

9.4 Forecasting Methodology 146

9.4.1 Pediatric Allergic Rhinitis Population 146

9.4.2 Diagnosed AR Patients 152

9.4.3 Percentage of Drug-Treated Patients 152

9.4.4 Drugs Included in Each Therapeutic Class 152

9.4.5 Launch and Patent Expiry Dates 155

9.4.6 1General Pricing Assumptions 156

9.4.7 Individual Drug Assumptions 157

9.4.8 Generic Erosion 166

9.4.9 Pricing of Pipeline Agents 166

9.5 Physicians and Specialists Included in This Study 167

9.6 About the Authors 171

9.6.1 Analyst 171

9.6.2 Therapy Area Director 171

9.6.3 Epidemiologist 172

9.6.4 Global Head of Healthcare 172

9.7 About GlobalData 173

9.8 Disclaimer 173

1.2 List of Figures

Figure 1: Immunological Mechanisms Involved in the Early- and Late-Phase Allergic Response 13

Figure 2: ARIA Classification of AR by Duration of Symptoms and Severity 16

Figure 3: Algorithm Used for the Management of AR in the 7MM* 25

Figure 4: Sales for AR in Japan by Drug Class, 2014-2024 123

1.1 List of Tables

Table 1: Airborne Allergens That Cause AR 11

Table 2: Common Symptoms of AR 14

Table 3: Treatment Guidelines for AR 21

Table 4: Most Commonly Prescribed Drugs for AR in the 7MM by Class, 2014 22

Table 5: Major Brands of INCS 28

Table 6: Management of AR, Country Profile-Japan 34

Table 7: Effects of Main Drug Classes on AR Symptoms 37

Table 8: Leading Branded Drugs Used to Treat AR, 2014 39

Table 9: Major Brands of Second- and Third-Generation Non-Sedating AHs 45

Table 10: Product Profile-AHs 48

Table 11: Efficacy of Bilastine in Symptomatic SAR Patients Age 12-70 Years 49

Table 12: Safety of Bilastine in Symptomatic SAR Patients Age 12-70 Years 50

Table 13: Oral AHs SWOT Analysis, 2014 51

Table 14: Global Sales Forecasts (USD m) for Oral AHs, 2014-2024 52

Table 15: Major Brands of Intranasal Ahs 54

Table 16: Major Brands of INCS 60

Table 17: Product Profile-INCS 62

Table 18: Efficacy of FP ANS and BDP ANS in AR Patients Age 18-72 Years 63

Table 19: Safety Profile of FP ANS and BDP ANS in AR Patients Age 18-72 Years 64

Table 20: INCS SWOT Analysis, 2014 65

Table 21: Global Sales Forecasts (USD m) for INCS, 2014-2024 66

Table 22: Product Profile-Dymista 71

Table 23: Efficacy of Dymista 72

Table 24: Safety of Dymista 73

Table 25: Dymista SWOT Analysis, 2014 74

Table 26: Global Sales Forecasts (USD m) for Dymista, 2014-2024 75

Table 27: Unmet Need and Opportunity in AR 86

Table 28: Late-Stage Pipeline for AR, 2014 108

Table 29: Product Profile-S-555739 109

Table 30: Completed Clinical Trials of S-555739 in AR Patients 111

Table 31: S-555739 SWOT Analysis, 2014 113

Table 32: Global Sales Forecasts (USD ) for S-555739, 2014-2024 114

Table 33: Product Profile-HP-3060 115

Table 34: HP-3060 SWOT Analysis, 2014 117

Table 35: Global Sales Forecasts (USD ) for HP-3060, 2014-2024 118

Table 36: Sales Forecasts (USD ) for AR in Japan, 2014-2024 122

Table 37: Key Events Impacting Sales for AR in Japan, 2014-2024 124

Table 38: AR Market-Drivers and Barriers in Japan, 2014-2024 124

Table 39: Abbreviations 141

Table 40: Key Launch Dates of the Currently Available AR Therapies 155

Table 41: Key Loss of Exclusivity Dates of the Currently Available AR Therapies 156

Table 42: High-Prescribing Physicians (non-KOLs) Surveyed, by Country 170

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com